Results 11 to 20 of about 9,857 (174)

Emerging Cross-Resistance to Cefiderocol and Ceftazidime-Avibactam in KPC-Producing <i>Klebsiella pneumoniae</i> During Ceftazidime-Avibactam Therapy. [PDF]

open access: yesAntibiotics (Basel)
Background/Objectives: Ceftazidime-avibactam (CAZ/AVI) and cefiderocol (FDC) retain activity against most clinical isolates of KPC-producing Klebsiella pneumoniae (KPC-Kp). Nevertheless, the emergence of cross-resistance between both agents has become an increasing clinical concern.
Riazzo C   +10 more
europepmc   +3 more sources

The β-Lactams Strike Back: Ceftazidime-Avibactam [PDF]

open access: yesPharmacotherapy, 2015
Gram‐negative resistance has reached a crucial point, with emergence of pathogens resistant to most or all available antibiotics. Ceftazidime‐avibactam is a newly approved agent combining ceftazidime and a novel β‐lactamase inhibitor with activity against multidrug‐resistant gram‐negative bacteria.
Evan J Zasowski   +2 more
exaly   +3 more sources

Colistin Does Not Potentiate Ceftazidime-Avibactam Killing of Carbapenem-Resistant Enterobacteriaceae in Vitro or Suppress Emergence of Ceftazidime-Avibactam Resistance. [PDF]

open access: yesAntimicrobial Agents and Chemotherapy, 2018
We tested ceftazidime-avibactam and colistin against 24 carbapenem-resistant Enterobacteriaceae (CRE) isolates by time-kill studies. Ceftazidime-avibactam at 0.25×, 1×, and 4× the MIC was bactericidal against 8%, 21%, and 88% of the isolates, respectively.
Hung T. Nguyen   +2 more
exaly   +3 more sources

Severe hypokalemia induced by ceftazidime-avibactam: Case report. [PDF]

open access: yesMedicine (Baltimore)
Rationale: Ceftazidime-avibactam is widely used to treat infections caused by carbapenem-resistant Gram-negative bacteria. Although it is generally considered safe, cases of severe hypokalemia associated with its use have rarely been reported.
Yuan Y, Gu Y, Bai W, Liu W, Li W, Yin Y.
europepmc   +3 more sources

Ceftazidime-Avibactam as Osteomyelitis Therapy: A Miniseries and Review of the Literature

open access: yesAntibiotics, 2023
Bone and joint infections (BJIs) caused by multidrug-resistant gram-negative bacteria are becoming a concern due to limited therapeutic options. Although not approved for these indications, an ever-growing amount of evidence supports the efficacy and safety of ceftazidime–avibactam as a therapy for osteomyelitis and prosthetic joint infections.
Mancuso, Alessandro   +5 more
openaire   +5 more sources

Clinical and genomic determinants associated with emergent ceftazidime-avibactam plus aztreonam non-susceptibility in ceftazidime-avibactam resistant <i>Escherichia coli</i>. [PDF]

open access: yesAntimicrob Agents Chemother
ABSTRACT Ceftazidime–avibactam (CZA) has revolutionized care for carbapenem-resistant Enterobacterales infections, yet increasing New Delhi metallo-β-lactamase (NDM) prevalence has driven use of CZA plus aztreonam (ATM/CZA).
Shropshire WC   +16 more
europepmc   +3 more sources

The Discovery of Ceftazidime/Avibactam as an Anti-Mycobacterium Avium Agent. [PDF]

open access: yesJournal of Antimicrobial Chemotherapy, 2017
To determine if ceftaroline and ceftazidime combined with avibactam are efficacious against pulmonary Mycobacterium avium complex (MAC) disease.First, we performed a concentration-effect study of ceftaroline and ceftaroline/avibactam against extracellular MAC in test tubes.
Tawanda Gumbo   +2 more
exaly   +3 more sources

Identification of a Novel Ceftazidime-Avibactam-Resistant KPC-2 Variant, KPC-123, in Citrobacter koseri Following Ceftazidime-Avibactam Treatment

open access: yesFrontiers in Microbiology, 2022
This study reported the identification of a novel ceftazidime-avibactam-resistant KPC-2 variant, KPC-123, in a Citrobacter koseri isolated from a patient in a Chinese hospital following ceftazidime-avibactam treatment of infection caused by OXA-232-producing Klebsiella pneumoniae.
Lin Wang   +3 more
openaire   +4 more sources

In-Vitro Activity of Ceftazidime-Avibactam and Comparator Agents Against Carbapenem-Resistant Gram-Negative Isolates at a Tertiary Care Hospital in Lahore, Pakistan: A Cross-Sectional Study. [PDF]

open access: yesMicrobiologyopen
Of 210 consecutive non‐duplicate carbapenem‐resistant Gram‐negative isolates collected at a tertiary care hospital in Lahore, Pakistan (December 2024–May 2025), 200 had a ceftazidime‐avibactam (CAZ–AVI) result; 70.5% were susceptible (141/200; 95% CI 63.7–76.7). Susceptibility varied by sample source (p = 0.008), being highest in blood cultures (81.2%),
Yunus F   +5 more
europepmc   +2 more sources

Ceftazidime-avibactam [PDF]

open access: yesRevista Española de Quimioterapia, 2021
Ceftazidime is a 3rd generation cephalosporin active against Pseudomonas aeruginosa. Avibactam is an inhibitor of class A, C and some class D β-lactamases. The antibacterial spectrum of ceftazidime-avibactam covers 95% of P. aeruginosa isolates and >99% of enterobacteria, including strains carrying extended-spectrum β-lactamases (ESBLs).
Matesanz, Mayra, Mensa, José
openaire   +2 more sources

Home - About - Disclaimer - Privacy